The WENA SEC filings page on Stock Titan provides access to the regulatory history of ANEW MEDICAL, INC., which, according to company disclosures and Commission reports, has been renamed Klotho Neurosciences, Inc. and now lists its common stock and warrants on the Nasdaq Stock Market under the symbols KLTO and KLTOW. These filings document the company’s transition, governance changes, financing actions and progress in its biopharmaceutical programs.
Recent Form 8‑K reports identify Klotho Neurosciences, Inc. as a Delaware corporation and an emerging growth company, and confirm its Nasdaq listings. One Form 8‑K describes the U.S. Food and Drug Administration granting Orphan Drug Designation for the company’s KLTO‑202 gene therapy candidate for the treatment of Amyotrophic Lateral Sclerosis (ALS). Another Form 8‑K discusses the commencement of manufacturing for a gene therapy candidate, while a later 8‑K outlines a letter agreement with AAVnerGene Inc. for manufacturing and development of KLTO‑202 using AAVnerGene’s platform technology.
An 8‑K/A filing provides additional context on board‑level changes by clarifying the effective date of a director’s resignation that occurred when the company was still known as ANEW Medical, Inc. A Form 12b‑25 (NT 10‑Q) explains a delay in filing a Quarterly Report on Form 10‑Q for the period ended June 30, 2025, citing the need for additional time to complete financial statements and obtain necessary review and signatures, while stating that no significant change in results of operations from the prior‑year period was anticipated.
Through these filings, users can see how the former WENA‑listed entity reports material events, regulatory designations, manufacturing arrangements and reporting timelines as it advances its Klotho gene‑based CNS therapy programs under the KLTO symbol.